Adult T-cell lymphoma/leukaemia refractory – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Tue, 23 Jun 2026 04:06:56 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Adult T-cell lymphoma/leukaemia refractory – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study Comparing Duvelisib with Gemcitabine or Bendamustine for Patients with Relapsed or Resistant T Cell Lymphoma Originating from T Follicular Helper Cells https://clinicaltrials.eu/trial/study-comparing-duvelisib-with-gemcitabine-or-bendamustine-for-patients-with-relapsed-or-resistant-t-cell-lymphoma-originating-from-t-follicular-helper-cells/ Wed, 29 Apr 2026 15:04:22 +0000 https://clinicaltrials.eu/trial/study-comparing-duvelisib-with-gemcitabine-or-bendamustine-for-patients-with-relapsed-or-resistant-t-cell-lymphoma-originating-from-t-follicular-helper-cells/ This clinical trial is focused on studying a type of blood cancer known as nodal T cell lymphoma, which originates from a specific type of T cells called T follicular helper (TFH) cells. The study is specifically for patients whose cancer has returned after treatment, known as relapsed, or has not responded to previous treatments, known as refractory. The trial will compare the effectiveness of a medication called Duvelisib against two other anti-cancer drugs, Gemcitabine and Bendamustine.

The purpose of the study is to evaluate how well Duvelisib works in extending the time patients live without their disease getting worse, compared to the other two drugs. Participants in the study will be randomly assigned to receive either Duvelisib or the doctor’s choice of Gemcitabine or Bendamustine. Duvelisib is taken orally in the form of hard capsules, while Gemcitabine and Bendamustine are administered intravenously, meaning they are given through a vein. The study will monitor participants over a period of up to three years to assess the progression of the disease and overall survival, as well as the quality of life and any side effects experienced.

This trial aims to provide valuable information on the best treatment options for patients with this type of lymphoma. By comparing these treatments, the study hopes to find the most effective way to manage the disease and improve patient outcomes. Participants will be closely monitored by healthcare professionals throughout the study to ensure their safety and well-being.

]]> Study of Selinexor, Ifosfamide, Etoposide, and Dexamethasone for Patients with Relapsed or Refractory Peripheral T-cell Lymphomas https://clinicaltrials.eu/trial/study-of-selinexor-ifosfamide-etoposide-and-dexamethasone-for-patients-with-relapsed-or-refractory-peripheral-t-cell-lymphomas/ Wed, 29 Apr 2026 14:29:19 +0000 https://clinicaltrials.eu/trial/study-of-selinexor-ifosfamide-etoposide-and-dexamethasone-for-patients-with-relapsed-or-refractory-peripheral-t-cell-lymphomas/ This clinical trial is focused on studying a type of cancer known as Peripheral T-cell Lymphoma, which has either returned after treatment or has not responded to previous treatments. The study is testing a combination of medications to see how well they work together. The medications being used in this study are Selinexor (also known by its code name KPT-330), Ifosfamide, Etoposide, and Dexamethasone. These medications are being tested together to see if they can help improve the condition of patients with this type of lymphoma.

The purpose of the study is to determine how effective this combination of medications is in treating the lymphoma. Participants in the study will receive these medications over a series of treatment courses. The study will monitor the response of the lymphoma to the treatment, looking for signs of improvement such as a reduction in the size of the cancer or a complete disappearance of the cancer. The study will also keep track of any side effects that participants may experience while taking these medications.

Throughout the study, participants will receive regular check-ups and tests to monitor their health and the progress of the treatment. The study aims to provide valuable information on whether this combination of medications can be a successful treatment option for patients with relapsed or refractory Peripheral T-cell Lymphoma. The results of this study could help improve future treatment options for this challenging condition.

]]>